Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014

Infection

Volumn 44, Issue 2, 2016, Pages 205-213

  Barchiesi, Francesco ^a   Orsetti, Elena ^a   Gesuita, Rosaria ^a   Skrami, Edlira ^a   Manso, Esther ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Azienda Ospedaliera Umberto I   (Italy)

Author keywords

Antifungal susceptibility testing; Candida albicans; Candida species; Candidemia; Mortality

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDEMIA; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEOPLASM; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SOLID; SURGICAL WARD; TERTIARY CARE CENTER; CANDIDA; CLASSIFICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; HUMANS; ITALY; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84944691132     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-015-0845-z     Document Type: Article

References (40)

1. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37.
2. Lionakis MS, Netea MG. Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog. 2013;9:e1003079.
3. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–9.
4. Tortorano A, Kibbler C, Peman J, et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359–66.
5. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet. 2003;3:685–702.
6. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005;43:1829–35.
7. Hassan I, Powell G, Sidhu M, et al. Excess mortality, length of stay and cost attributable to candidaemia. J Infect. 2009;59:360–5.
8. Bassetti M, Taramasso L, Nicco E, et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198.
9. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816–23.
10. Mayr A, Aigner M, Lass-Flörl C. Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect. 2011;17:1–12.
11. Bassetti M, Merelli M, Righi E, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013;51:4167–72.
12. Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.
13. Nieto MC, Tellería O, Cisterna R. Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility. Diagn Microbiol Infect Dis. 2015;81:34–40.
14. Mermel LA, Allon M, Bouza E. Clinical Pratice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Disease Society of America. Clin Infect Dis. 2009;49:1–45.
15. Pappas PG, Kauff man CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.
16. Pfaller MA and Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–56.
17. Tortorano A, Prigitano A, Lazzarini C, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013;41:655–62.
18. Cisterna R, Ezpeleta G, Tellaria O, et al. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospital in Spain. J Clin Microbiol. 2010;48:4200–6.
19. Pemán J, Cantón E, Quindós G, et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother. 2012;67:1181–7.
20. Poikonen E, Lyytikäinen O, Anttila VJ, et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007. BMC Infect Dis. 2010;10:312.
21. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000–2005. Infect Control Hosp Epidemiol. 2008;29:978–80.
22. Chen S, Slavin M, Nguyen Q, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis. 2006;12:1508–16.
23. Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38:65–9.
24. Nucci M, Queiroz-Telles F, Alvarado-Matute T, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8:e59373.
25. Guimarães T, Nucci M, Mendonça JS, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J Infect Dis. 2012;16:e442–7.
26. Bassetti M, Molinari MP, Mussap M, et al. Candidemia in internal medicine departements: the burden of a rising problem. Clin Microbiol Infect. 2013;19:e281–4.
27. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;4:5–24.
28. Lockhart SR, Iqbal N, Cleveland AA, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two US cities from 2008 to 2011. J Clin Microbiol. 2012;50:3435–42.
29. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55:1352–61.
30. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5 year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48:1366–77.
31. Pfaller MA, Moet GJ, Messer SA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program (2008–2009). J Clin Microbiol. 2011;49:396–9.
32. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19:e343–53.
33. Montagna MT, Caggiano G, Lovero G, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection. 2013;41:645–53.
34. Leroy O, Gangneux JP, Montravers P, et al. AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8.
35. Bassetti M, Trecarichi EM, Righi E, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in two italian university hospitals. Diagn Microbiol Infect Dis. 2007;58:325–31.
36. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi institutional study. Clin Infect Dis. 2006;43:25–31.
37. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5.
38. Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect. 2014;20:42–8.
39. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50:1199–203.
40. Posteraro B, Spanu T, Fiori B, et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensitre YeastOne over nine years at a large italian teaching hospital. J Antimicrob Chemother. 2015;59:3944–55.